A Novel Tandem Mass Spectrometry Method for Rapid Confirmation of Medium- and Very Long-Chain acyl-CoA Dehydrogenase Deficiency in Newborns by ter Veld, Frank et al.
A Novel Tandem Mass Spectrometry Method for Rapid
Confirmation of Medium- and Very Long-Chain acyl-CoA
Dehydrogenase Deficiency in Newborns
Frank ter Veld*, Martina Mueller, Simone Kramer, Ulrike Haussmann, Diran Herebian, Ertan Mayatepek,
Maurice D. Laryea, Sonja Primassin, Ute Spiekerkoetter
Department of General Pediatrics, Heinrich- Heine -University, Du ¨sseldorf, Germany
Abstract
Background: Newborn screening for medium- and very long-chain acyl-CoA dehydrogenase (MCAD and VLCAD,
respectively) deficiency, using acylcarnitine profiling with tandem mass spectrometry, has increased the number of patients
with fatty acid oxidation disorders due to the identification of additional milder, and so far silent, phenotypes. However,
especially for VLCADD, the acylcarnitine profile can not constitute the sole parameter in order to reliably confirm disease.
Therefore, we developed a new liquid chromatography tandem mass spectrometry (LC-MS/MS) method to rapidly
determine both MCAD- and/or VLCAD-activity in human lymphocytes in order to confirm diagnosis.
Methodology: LC-MS/MS was used to measure MCAD- or VLCAD-catalyzed production of enoyl-CoA and hydroxyacyl-CoA,
in human lymphocytes.
Principal Findings: VLCAD activity in controls was 6.9560.42 mU/mg (range 1.95 to 11.91 mU/mg). Residual VLCAD activity
of 4 patients with confirmed VLCAD-deficiency was between 0.3 and 1.1%. Heterozygous ACADVL mutation carriers showed
residual VLCAD activities of 23.7 to 54.2%. MCAD activity in controls was 2.3860.18 mU/mg. In total, 28 patients with
suspected MCAD-deficiency were assayed. Nearly all patients with residual MCAD activities below 2.5% were homozygous
985A.G carriers. MCAD-deficient patients with one other than the 985A.G mutation had higher MCAD residual activities,
ranging from 5.7 to 13.9%. All patients with the 199T.C mutation had residual activities above 10%.
Conclusions: Our newly developed LC-MS/MS method is able to provide ample sensitivity to correctly and rapidly
determine MCAD and VLCAD residual activity in human lymphocytes. Importantly, based on measured MCAD residual
activities in correlation with genotype, new insights were obtained on the expected clinical phenotype.
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Introduction
If undiagnosed and untreated, fatty acid oxidation defects
(FAOD), such as medium- and very long-chain acyl-CoA
dehydrogenase deficiency (MCADD and VLCADD, respectively),
are associated with high morbidity and mortality [1]. Clinical
presentation of VLCADD may include cardiomyopathy, meta-
bolic encephalopathy, hypoglycaemia and rhabdomyolysis.
MCADD is associated with hepatic symptoms that are predom-
inantly related to intercurrent illnesses or prolonged fasting. Thus,
early detection by newborn screening (NBS) is absolutely essential
for achieving a more favourable outcome and indeed, disease
mortality and morbidity is significantly reduced [2,3].
However, NBS for MCADD and VLCADD using tandem mass
spectrometry screening identifies false-positive cases and the
outcome of the expanded NBS program in Germany, including
MCADD and VLCADD, was recently assessed by Schulze et al.
demonstrating that the positive predictive values for MCADD and
VLCADD were 25.8 and 3.1%, respectively [4]. In contrast to
medium-chain acylcarnitines, mild accumulation of long-chain
acylcarnitines is observed in healthy children due to activated
mitochondrial fatty acid oxidation during catabolism [5]. Further-
more, VLCADD patients may well present with normal
confirmatory secondary screening after day 3 of life during
anabolism [6]. Taken together, each newborn with an acylcarni-
tine profile suggestive of MCADD or VLCADD needs further
confirmatory diagnosis. Genotyping for prevalent mutations, i.e.
the 985A.G mutation in case of MCADD, may represent rapid
and cost-effective confirmatory techniques. However, the use of
extended, and thus both time-consuming and expensive, mutation
screening was reported to be necessary, particularly for suspected
MCADD patients who are not of European descent, as recently
reviewed by Leonard et al. [7]. Likewise, great molecular
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6449heterogeneity in VLCADD [8] makes extended mutation
screening obligatory in most cases. Genotyping does, therefore,
not always constitute a swift and cost-effective confirmatory
diagnostic technique for a suspected FAOD in all cases.
In this paper we present a novel, cost-effective and rapid
method for the measurement of MCAD and VLCAD activity in
human lymphocytes to correctly identify patients and to confirm




Whole blood specimens were obtained from subjects with
biochemical indication of MCADD or VLCADD, as identified in
NBS, their parents and siblings. As the determination of MCAD
and/or VLCAD residual activity constitutes a routine procedure
performed by our laboratory, not being part of a scientific study in
any way or form, informed consent from subjects, or their parents,
was obtained by the referring physicians in oral fashion. The study
was performed according to the rules of the Declaration of
Helsinki and approved under study number 3230 by the ethical
review board of Heinrich-Heine-University Du ¨sseldorf.
Reagents
Palmitoleoyl-CoA (C16:1-CoA), palmitoyl-CoA (C16:0-CoA)
and octanoyl-CoA (C8:0-CoA) were purchased from Sigma
(Deisenhofen, Germany) as Li
+ salts and stored at 220uC.
Ferrocenium hexafluorophosphate was obtained from Sigma-
Aldrich (Deisenhofen, Germany).
Procedures
Isolation of lymphocytes from blood samples.
Lymphocytes were isolated from 2 mL of whole blood using
Ficoll-Paque
TM Plus (Amersham) and Leucosep H (Greiner Bio
One) tubes as described previously [9].
VLCAD and MCAD enzyme assay conditions.
Lymphocytes were resuspended in medium (200 mM
ferrocenium hexafluorophosphate in 100 mM Tris-HCl or
10 mM NH4Ac for HPLC and LC-MS/MS analysis,
respectively) to a final protein concentration of 30 mg ? mL
21.
Duplicate enzyme reactions for 5 min. at 37uC and pH=8.0 were
started by adding 4 mL of 5 mM C16:0-CoA as substrate to a total
reaction volume of 100 mL. For HPLC analysis, quenching was
achieved by adding 10 mL of 2 M HCl, followed by 5 min. of
incubation on ice and neutralization with 2 M KOH. For LC-
MS/MS analysis, the reaction was quenched by adding 100 mLo f
220uC acetonitrile. Subsequently, proteins were removed by
precipitation at 13000 rpm for 5 min. and by filtering the
supernatant through 96-well 1.2 mm filter plates (Millipore,
Schwalbach, Germany). C16:0-CoA was replaced by C8:0-CoA
in the MCAD assay, at a concentration of 5 mM.
High-pressure-liquid-chromatography analysis. VLCAD
assay products, C16:1-CoA and C16:OH-CoA, and the C16:0-
CoA substrate were measured based on a method published by
Woldegiorgis et al. [10]. Briefly, a Phenomenex C18(2) Luna
column (250 mm64.6 mm65 mm) in combination with a C18
Luna guard column were used. The two mobile-phase solvents
were acetonitrile and 25 mM KH2PO4, pH=6.9. Following
2 min. of 70% KH2PO4 and 30 5 ACN, a three-step linear
gradient was used; 1) 70% KH2PO4 reduced to 60% and 30%
acetonitrile increased to 40% over 5 min. 2) 60% KH2PO4
reduced to 54% and 40% acetonitrile increased to 46% over
9 min. 3) 54% KH2PO4 reduced to 38% and 46% acetonitrile
increased to 62% over 5 min. Next, the 38% KH2PO4/62%
acetronitrile mixture was run for 5 min. Finally, the system was
equilibrated for 5 min. The injection volume was 10 mL at a flow
rate of 1.5 mL/min. The acyl-CoA esters were detected at 254 nm
and 16:1-CoA, C16:OH-CoA and C16:0-CoA eluted at 11,6; 16,6
and 17,5 min, respectively. Quantitation was based on peak areas,
with the initial substrate C16:0-CoA amount set to 20 nmol.
Tandem mass spectrometry analysis. In quenched
VLCAD and MCAD assay samples, C16:1-CoA; C16:OH-CoA;
C16:0-CoA and C8:1-CoA; C8:OH-CoA; C8:0-CoA,
respectively, were quantified by LC-MS/MS. A Waters 2795
Alliance HPLC system (Waters, Milford, UK), equipped with a
thermostated autosampler, was used for solvent delivery and
sample introduction. Assay samples were placed in a cooled
sample tray (15uC) and 5 mL was injected onto a C18(2)
Phenomenex Luna column (10062.0 mm63 mm). C16:OH-
CoA, C16:1-CoA and C16:0-CoA were eluted isocratically with
55% (v/v) acetonitrile in 10 mM NH4Ac (pH was not adjusted
and was approx. 6.7) at a flow rate of 200 mL/min. Similarly,
C8:OH-CoA, C8:1-CoA and C8:0-CoA were eluted isocratically
with 30% (v/v) acetonitrile in 10 mM NH4Ac. The eluate was
delivered into a Quattro Micro MS/MS (Micromass, Cambridge,
UK) with an ESI probe in positive ion mode. Injection interval
was 5 min. Nitrogen was used as drying gas at 650 L/h. Collision
energy was 35 eV and argon was used as collision gas.
Declustering potential was 45 V and ion source temperature was
100uC. Compounds were detected in the multiple reaction
monitoring (MRM) mode with the following mass transitions for
the VLCAD assay: C16:OH-CoA, m/z 1022.4 R 515.2, C16:1-
CoA, m/z 1004.4 R 497.2 and C16:0-CoA, m/z 1006.4 R
499.2, respectively, and C8:OH-CoA, m/z 910.4 R 403.2, C8:1-
CoA, m/z 892.4 R 385.3 and C8:0-CoA, m/z 894.4 R 387.2,
respectively, for the MCAD assay.
Quantitation was based on peak area ratios, with the initial
substrate C16:0-CoA or C8:0-CoA amount set to 20 nmol.
Identification of mutations in the ACADM and ACADVL
gene. Genomic DNA from whole blood was isolated using DNA
Mini kit (Qiagen, Hilden, Germany). Polymerase chain reaction
(PCR) was used to amplify all twelve ACADM exons, including part
of the flanking intron sequences as previously described [11].
ACADVL, containing 20 exons, was analyzed according to
Spiekerkoetter et al. [9]. The amplified DNA fragments were
separated by electrophoresis and extracted (QIAquick Gel
Extraction kit, Quiagen). PCR products were subjected to DNA
sequence analysis using the Cycle sequencing kit, (Applied
Biosystems, Weiterstadt, Germany). Analysis was performed
using an Applied Biosystems Prism 310 Genetic Analyser.
Statistical methods
Data were acquired and analysed using MassLynx NT v4.0
(Micromass, UK). Reported data are presented as means6stan-
dard error of the mean (s.e.m.). Statistical analyses were performed
using Student’s t-test. Differences between means were considered
significant if p,0.05.
Results
Characterization and validation of the acyl-CoA
dehydrogenase assays
Representative VLCAD assay multiple reactant monitoring
chromatograms are shown in Figure 1. The sample was either
quenched instantly by adding 220uC acetonitrile, subsequent to
substrate (C16:0-CoA) addition (Fig. 1, A and B), or was incubated
for 5 minutes at 37uC (Fig. 1, C and D). The hydroxyl-CoA
MS/MS VLCAD / MCAD Measurement
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515.2) at 1.9 min. and the enoyl-CoA peak (C16:1-CoA fragment
ion, m/z 1004.4 R 497.2) eluted at 3.2 min. The observed C16:1-
CoA peak eluting at 4.0 min. was independent of assay incubation
time or sample amount and was solely dependent on palmitoyl-
CoA substrate concentration, most likely identifying it as C16:1-
cis-9-CoA impurity in the commercial palmitoyl-CoA preparation.
As enoyl-CoA products are rapidly converted into hydroxyacyl-
CoA by matrix 2-enoyl-hydratases, in order to avoid product
inhibition in-vivo [12,13], it was critical to include hydroxyacyl-
CoA as acyl-CoA dehydrogenase product to avoid underestima-
tion of catalytic turnover.
The oxidation products in the MCAD assay, C8:OH-CoA and
C8:1-CoA, and the added substrate C8:0-CoA had fragment
masses of m/z 910.4 R 403.2, 892.4 R 385.3 and 894.4 R 387.2,
respectively. MCAD and VLCAD activities in lymphocytes were
linear up to 20 min, proportional to the amount of protein added
in the range of 10 to 50 mg and were independent of ferrocenium
hexafluorophosphate electron acceptor concentrations above
50 mM.
The inter-assay variation (CV) for the HPLC and LC-MS/MS
method were determined by measuring the VLCAD activity in the
same control lymphocytes on 8 different days and were 9% and
13%, respectively. To determine the intra-assay variation (CV),
VLCAD activity was measured in one control lymphocyte sample
in triplicate on two consecutive days. Intra-assay variations were
3% and 4% for the HPLC and LC-MS/MS method, respectively.
We compared results obtained with our newly developed LC-
MS/MS VLCAD assay with VLCAD activities determined by
HPLC. In a direct comparison of VLCAD activities in human
lymphocytes, the LC-MS/MS method correlates well with the
HPLC assay (Fig. 2). We observed that correlation between the
established HPLC and newly developed LC-MS/MS method was
excellent (r=0.941) and Syx was60.804 (Fig. 2).
Determination of residual VLCAD activities in patients
In total, 52 subjects were measured with our LC-MS/MS
VLCAD assay. Four were identified as VLCADD patients and 9
were heterozygous carriers of an ACADVL mutation (Fig. 2).
VLCADactivitiesmeasuredbyLC-MS/MSinthesamplescollected
from normal subjects (n=36) ranged from 1.95 to 11.91 nmol ?
min
21 ? mg protein
21, with a mean6SE value of 6.9560.42 nmol ?
min
21 ? mg protein
21 (Fig. 2). Average residual VLCAD activities of
four confirmed patients, being homozygous carriers of an ACADVL
mutation, was 0.1360.07 nmol ? min
21 ? mg protein
21, represent-
ing residual activities between 0.02 and 0.34 nmol ? min
21 ? mg
protein
21 (Fig. 2). In confirmed heterozygous carriers of an ACADVL
mutation, residual VLCAD activity ranged from 1.07 to 3.77 nmol ?
Figure 1. Multiple Reactant Monitoring (MRM) chromatograms of quenched VLCAD assay samples. C16:OH-CoA, m/z 1022.4 R 515.2 (A
and B) and C16:1-CoA, m/z 1004.4 R 497.2 (C and D) after 0 (A and C) and 5 (B and D) min. of incubation.
doi:10.1371/journal.pone.0006449.g001
MS/MS VLCAD / MCAD Measurement
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21 ? mg protein
21. VLCAD activity measurements with HPLC
revealed comparable results, but homozygous ACADVL mutation
carriers had a higher average residual VLCAD activity of
0.5560.01 nmol ? min
21 ? mg protein
21 (Fig. 2).
Determination of residual MCAD activities in patients
MCAD activities measured by LC-MS/MS in the samples
collected from normal subjects (n=6) ranged from 1.82 to
2.78 nmol ? min
21 ? mg protein
21, with a mean6SE value of
2.3860.18 nmol ? min
21 ? mg protein
21. Table 1 lists 28
examined cases that were assayed for MCAD activity, parents of
newborns are highlighted. With the exception of cases 4, 6 and 8
all patients with residual MCAD activities below 2.5% were
homozygous carriers of the 985A.G mutation. MCADD patients
with other mutations had higher MCAD residual activities,
ranging from 5.7 to 13.9%. Patients carrying one 199T.C
mutation presented with residual activities above 10%. Confirmed
985A.G heterozygotes (cases 20, 22 and 23) had residual MCAD
activities above 24% of controls (Table 1).
Genotypes of MCAD-deficient patients
Mutation analysis revealed that 8 out of 18 patients were
985A.G homozygotes (Table 1). Cases 4 and 8 presented with an
insertion at position 245, as reported previously by Gregersen et al.
and Maier et al. [14,15], and were heterozygous for a splicing
mutation (IVS9+2T.C). In addition, multiple other intronic
sequence variants (IVS) were observed (IVS2-32C.G,
IVS3+10T.C, IVS5+32C.G, IVS7-22C.A). Case 6, in addi-
tion to mutation 985A.G, carried the 347G.A mutation, a
mutation previously described as severe [14,16]. To the best of our
knowledge, case 14 carried a novel mutation and was homozygous
for 823A.G. Case 15 was a homozygous carrier of the 157C.T
mutation, reported earlier [14–16]. Cases 16 and 17 were
compound heterozygous for mutations 985A.G and 199T.C,
as reported earlier [11,14]. An insertion at position 1140 was
identified in case 18 and was also previously not reported. In cases
18, 24, 26–28 a FAOD was clinically suspected but the subjects
turned out not to carry a mutation on both ACADM alleles. Case
21, parent of case 12, had multiple heterozygous intervening
sequences (IVS2-32C.G, IVS3+10T.C, IVS5+32C.G, IVS6-
14A.G and IVS7-22C.A). Cases 12 and 13 originated from
different families and were both heterozygous carriers of the same
above described intervening sequences, in addition to their
classical 985A.G mutation (Table 1).
Correlation of genotype with MCAD residual activity and
C8:0-carnitine concentration
As indicated in Table 1, initial C8:0-carnitine does not always
correlate with genotype and residual enzyme activity. However, a
high C8:0-carnitine above .10 mM was only observed in
MCADD patients with residual MCAD activities below 2% of
controls and the homozygous 985A.G mutation (Fig. 3).
Discussion
Our newly developed tandem MS method for the determination
of MCAD- and VLCAD-enzyme activities in human lymphocytes
is able to provide ample sensitivity to correctly and rapidly confirm
diagnosis of the respective disorder in individuals identified by
newborn screening. This technique is of great importance because
long-chain acylcarnitines are elevated in healthy children or
VLCAD heterozygotes, due to activated fatty acid oxidation in the
first 2–3 days of life, and are thus interfering with NBS results. In
case of MCADD, this assay also offers the possibility to predict
severity of expected clinical phenotype based on residual MCAD
activities and correlating genotype.
As the LC-MS/MS analytical apparatus is available in all NBS
laboratories worldwide, it was important to develop an analysis
Figure 2. Comparison of results of the standard HPLC assay and the LC-MS/MS assay from the same lymphocyte sample. Total
number of subjects tested was 52. (N) Normal controls. (m) Confirmed heterozygous ACADVL mutation carriers. (#) Confirmed homozygous ACADVL
mutation carriers.
doi:10.1371/journal.pone.0006449.g002
MS/MS VLCAD / MCAD Measurement
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newly developed method thus offers the possibility to determine
MCAD or VLCAD activity in one single setup, without
exchanging columns, and lacking complex gradients.
Residual VLCAD activity in VLCADD patient lymphocytes
Enzyme activities of VLCAD in human lymphocytes from
healthy controls were 6.9560.42 nmol ? min
21 ? mg protein
21
(n=36) and are similar to control values reported previously by
other laboratories [17–19]. Figure 2 clearly shows that heterozy-
gous carriers can not be discriminated from healthy controls in all
cases. However, most importantly, VLCADD patients confirmed
by molecular analysis of the ACADVL gene can unequivocally be
identified based on the determination of residual VLCAD activity
in isolated lymphocytes.
Correlation of residual MCAD activity with ACADM
genotype
Unlike VLCADD with molecular heterogeneity, MCAD-
deficiency possesses the prevalent 985A.G mutation and, since
NBS, the less common 199T.C mutation. The total number of
individual ACADM mutations reported so far is approx. 25, as
reviewed in [14]. We therefore, attempted to correlate residual
MCAD-activities with our ACADM genotyping results. This was
not pursued for VLCAD activities and corresponding mutations in
the ACADVL gene, also because of much greater molecular
heterogeneity and due the limited number of observed homozy-
gous ACADVL mutation carriers.
MCAD activities in healthy controls were 2.3860.18 nmol ?
min
21 ? mg protein
21, (n=6) being in agreement with previous
reports [17,20,21]. The MCAD assay was applied in lymphocyte
samples from 28 subjects with suspected MCAD-deficiency. In 18
individuals, diagnosis was confirmed by mutational analysis
(Table 1). All patients with the homozygous, classical 985A.G
mutation had residual MCAD activities below 2.5%, therefore
well in line with previous reports that identify the homozygous
status of the 985A.G mutation as severe clinical phenotype
[11,16]. The 985A.G mutation was the prevalent MCAD
mutation before the NBS era and patients were identified because
of hypoglycaemia or hepatopathy [16]. In addition to mutation
985A.G, one MCADD patient was carrier of the 347G.A
mutation, a mutation previously described as severe [14,16], this
again is in excellent agreement with a low residual MCAD activity
of 1.1%. The more recent 199T.C mutation [14] was identified
in a significant number of children since implementation of NBS
and is considered to induce a much milder MCADD variant [14].
In our cohort, this mutation was identified three times, two in
combination with the 985A.G mutation, and all three resulted in
significantly higher residual MCAD activities of approx. 11%, as
compared to patients being homozygous for the 985A.G
mutation. Also demonstrating that MCADD severity, in case of
compound heterozygosity, is determined by the mutation that is
known to be the mildest of the two, in this case the 199T.C
mutation [14]. In addition, patients with a heterozygous 245insT
mutation and a second splicing IVS9+2T.C mutation had
comparably lower residual activities of ,2.5%. For the homozy-
gous 157C.T mutation, reported earlier by [14–16] to result in a
mild clinical phenotype, enzymatic analysis now revealed that this
mutation leads to 9.3% residual MCAD activity. Interestingly, two
unrelated cases presented with the 985A.G mutation plus
identical mutations in intervening ACADM sequences (IVS2-
32C.G, IVS3+10T.C, IVS5+32C.G, IVS6-14A.G and
IVS7-22C.A) and both had residual MCAD activities of 6%.
Heterozygous carriers of the 985A.G mutation without a second
mutation (cases 20, 22 and 23) had residual MCAD activities of
24% or higher (Table 1).
The use of plasma octanoyl-carnitine levels in newborn
screening for MCADD
In our hands, measured plasma octanoyl-carnitine (C8:0) levels,
based on the initial newborn screening dried blood spot, indeed
functions as sensitive and specific marker for MCADD (Fig. 3).
However, the C8:0-carnitine values measured are unable to
discriminate between MCADD of different severity. This also applies
Table 1. Octanoyl-CoA oxidation, plasma medium-chain
acylcarnitine levels and gene analysis of both ACADM alleles in











1 0.4% 985A.G9 8 5 A .G 21.00 6.30
2 0.5% 985A.G9 8 5 A .G 12.50 3.13
3 0.5% 985A.G9 8 5 A .G 19.70 2.64
4 0.6% 245ins.TI V S 9 +2T.C
5 6.00
5 1.0% 985A.G9 8 5 A .G 0.97 0.85
6 1.1% 985A.G3 4 7 G .A 3.75 4.76
7 1.1% 985A.G9 8 5 A .G
8 1.3% 245ins.TI V S 9 +2T.C
5 7.73
9 1.7% 985A.G9 8 5 A .G 8.70 2.80
10 1.7% 985A.G9 8 5 A .G 12.00 1.42
11 2.3% 985A.G9 8 5 A .G 3.40 2.30
12 5.7% 985A.GI V S
6 2.80 1.48
13 6.3% 985A.GI V S
6 7.23 2.51
14 7.5% 823A.G8 2 3 A .G 1.90 2.57
15 9.3% 157C.T1 5 7 C .T 1.65
16 10.2% 985A.G1 9 9 T .C 4.27
17 11.8% 985A.G1 9 9 T .C 1.82
18 13.9% 1140ins.G1 9 9 T .C 0.48
19
7 24.5% wild-type wild-type
20
3 27.2% 985A.G wild-type
21
3 30.8% wild-type IVS
6
22
7 33.5% 985A.G wild-type
23
4 33.6% 985A.G wild-type
24
7 47.5% wild-type wild-type
25
4 53.4% 199T.C wild-type
26
7 69.9% wild-type wild-type
27
7 76.1% wild-type wild-type
28
7 76.5% wild-type wild-type
Case 1 to 18 were identified in NBS, with the exception of 4 and 8.
1Relative residual MCAD enzyme activities are presented as a percentage of the
mean of lymphocytes from healthy control (2.38 nmol ? min
21 ? mg
21,n=6 ) .
2First octanoylcarnitine specimen (C8:0 I) obtained on day 2–5 of life and
subsequent repeat specimen (C8:0 II) are shown in mmol ? L




5Intervening sequences: IVS2-32C.G, IVS3+10T.C, IVS5+32C.G, IVS7-22C.A.
6Intervening sequences: IVS2-32C.G, IVS3+10T.C, IVS5+32C.G, IVS6-14A.G
and IVS7-22C.A.
7subjects with clinical suspicion of MCADD.
doi:10.1371/journal.pone.0006449.t001
MS/MS VLCAD / MCAD Measurement
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well in line with a previous report from Chace and co-workers [22].
Possible limitations of this study
The use of isolated peripheral blood lymphocytes may well not
be fully representative for all individual organs that are
differentially afflicted by MCADD or VLCADD. Of note, studies
in fibroblasts would obviously present similar limitations. Further-
more, the use of ferrocenium as artificial oxidizing agent in our in-
vitro assay, instead of electron transfer flavoprotein in-vivo, may
possibly obscure alterations in MCAD and VLCAD activity
induced by mutations that impair flavin adenine dinucleotide
binding and/or electron transfer flavoprotein interaction.
Conclusions
Taken together, we have developed a new assay that allows fast
and reliable determination of MCAD and VLCAD residual
activity in human lymphocytes. This method takes advantage of
LC-MS/MS detection and can be implemented in any NBS
laboratory using LC-MS/MS technique. Both methods provide
reference values for MCAD and VLCAD enzyme activity in
lymphocytes from healthy controls that correspond well with
published rates in literature. Importantly, both methods provide
ample sensitivity to discriminate not only patients from healthy
individuals but, in case of MCADD, this method also offers the
possibility to differentiate between clinical phenotypes of different
severity based on residual MCAD activities, in line with their
genotype.
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